The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1505
Influenza Vaccine for 2016-2017
The full article is available to subscribers Subscriber Login   
Revisions:
10/19/16: A sentence regarding Flublok Quadrivalent has been added to the "Quadrivalent vs Trivalent" section.
12/7/16: In Table 2, the recommended age in for FluLaval Quadrivalent was changed to ≥6 months (from ≥3 years).

Annual vaccination against influenza A and B viruses is recommended for everyone ≥6 months old without a specific contraindication.1

EFFECTIVENESS — The effectiveness of seasonal influenza vaccine in preventing influenza illness depends on the match between the vaccine and circulating strains. Vaccine effectiveness is highest (50-60%) when the match is close, but even when the match is poor, vaccination has been shown to reduce the risk of laboratory-confirmed influenza, hospitalization for influenza, and death.2,3 For the 2015-2016 influenza season, the adjusted overall effectiveness of the seasonal influenza vaccine against influenza A and B viruses was 47%.4

Quadrivalent vs Trivalent – All of the trivalent and quadrivalent seasonal influenza vaccines available in the ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Influenza Vaccine for 2016-2017
Article code: 1505a
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian